In a filing, Cogent Biosciences Inc revealed its Director Fairmount Funds Management LLC acquired Company’s shares for reported $25.0 million on Jul 10 ’25. In the deal valued at $9.00 per share,2,777,777 shares were bought. As a result of this transaction, Fairmount Funds Management LLC now holds 9,003,418 shares worth roughly $146.49 million.
Then, Pinnow Cole bought 43,750 shares, generating $332,412 in total proceeds. Upon buying the shares at $7.60, the Chief Commercial Officer now owns 45,848 shares.
Raymond James initiated its Cogent Biosciences Inc [COGT] rating to a Strong buy in a research note published on September 03, 2025; the price target was $30. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early March with a ‘”a Sector outperform”‘ rating. Needham also remained covering COGT and has decreased its forecast on December 11, 2024 with a “Hold” recommendation from previously “Buy” rating. Robert W. Baird revised its rating on February 26, 2024. It rated COGT as “a Neutral” which previously was an “an Outperform”.
Price Performance Review of COGT
On Friday, Cogent Biosciences Inc [NASDAQ:COGT] saw its stock jump 0.49% to $16.27. Over the last five days, the stock has gained 3.24%. Cogent Biosciences Inc shares have risen nearly 49.95% since the year began. Nevertheless, the stocks have risen 108.59% over the past one year.
How much short interest is there in Cogent Biosciences Inc?
A steep rise in short interest was recorded in Cogent Biosciences Inc stocks on 2025-09-30, growing by 3.94 million shares to a total of 17.01 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 13.07 million shares. There was a rise of 23.18%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 08, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $11 price target.
